Skip to main content

Immunology

Best Rheumatologists (7.19.2024)

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
Systemic sclerosis sine scleroderma Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc. https://t.co/vIYSJr7blB https://t.co/fDtLXtM09E
Dr. John Cush @RheumNow( View Tweet )
Pathogenesis of Autoimmune Liver Disease (ALDs) ALDs, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage https://t.co/acgwwglKve https://t.co/ZDpF1VhBlc
Dr. John Cush @RheumNow( View Tweet )

Updated EULAR Recommendations on the Treatment of Systemic Sclerosis

Medscape

Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.

The new recommendations (n=20)

Read Article
Does B Cell Depletion Matter? Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria. https://t.co/SX7BkX3w1T https://t.co/H1rD0n8GnK
Dr. John Cush @RheumNow( View Tweet )
Pollution and Autoimmunity (7.12.2024) Dr. Jack Cush reviews the news and journal articles from the past week on https://t.co/V10S4oVFsv. https://t.co/c4Eo4EpOj8
Dr. John Cush @RheumNow( View Tweet )

Pathogenesis of Autoimmune Liver Disease

EurekAlert!

Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage. These diseases are increasingly prevalent, but their pathogenesis remains

Read Article
Full read, comprehensive review of NLRP3 inflammasome & its role in inate immunity (eg, infections), but also lifestyle (obesity, diabetes, NAFLD, heart/lung disease, periodontitis) and autoimmune diseases https://t.co/rCk9ncEsGA https://t.co/qc9eSIAVYe
Dr. John Cush @RheumNow( View Tweet )

PNAS & Nature Insights into Lupus Pathogenesis

Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder. 

Read Article

Progress in SLE with new mRNA CAR-T cell Trial

Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial. 

The investigational drug,

Read Article
Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr
Dr. John Cush @RheumNow( View Tweet )

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma

Read Article

ICYMI: BSR Guideline on Management of Sjogren’s Syndrome

Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and

Read Article

Review of Amyloidosis

EurekAlert!

The New England Journal of Medicine has published a review of systemic amyloidosis

"Amyloidosis, a systemic disease that manifests in various ways, should be in the differential

Read Article

EULAR 2024 Rheumatology Roundup (6.21.2024)

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article

Damage in Childhood Lupus

EurekAlert!

Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which could allow earlier

Read Article
#opportunistic inf in #autoimmune dz 🎤 @khyrich 👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸) 👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6 👉 🙅‍♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️ 🔗#eular 2022 guide: https://t.co/PIpGpTrH28 #eular2024 #rheumx @RheumNow https://t.co/kouXvradiC
Artem Minalyan, MD, DABOM @AMinalyan( View Tweet )
OP0140-When should we give #pneumococcal #vaccine to pts starting MTX? Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX ⏩Vaccinate patients before starting MTX! @RheumNow #EULAR2024

Mrinalini Dey @DrMiniDey( View Tweet )

Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively? VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed. I’ll admit, I’m still not game! #EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov
David Liew @drdavidliew( View Tweet )
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts ▶️ #Shingrix works 👍Pts followed to 60 months #EULAR2024 @eular_org @RheumNow #OP0020 https://t.co/8ORC3Nd2FK

Janet Pope @Janetbirdope( View Tweet )

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

Lupus Research Alliance Grants for Lupus Innovation

EurekAlert!

The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). They will conduct innovative research to uncover the underlying mechanisms and identify novel targets and pathways that could be harnessed

Read Article

SLE Cost of Care and Disease Activity

A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. 

The study included

Read Article

"Don't You Know Who I am?" (5.17.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article